These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 30101000)

  • 1. PD-L1 expression comparison between primary and relapsed non-small cell lung carcinoma using whole sections and clone SP263.
    Munari E; Zamboni G; Lunardi G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Hoque MO; Moretta F; Mingari MC; Pegoraro MC; Mariotti FR; Vacca P; Moretta L; Bogina G
    Oncotarget; 2018 Jul; 9(54):30465-30471. PubMed ID: 30101000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformance Assessment of PD-L1 Expression Between Primary Tumour and Nodal Metastases in Non-Small-Cell Lung Cancer.
    Xu H; Chen X; Lin D; Zhang J; Li C; Zhang D; Zhang X
    Onco Targets Ther; 2019; 12():11541-11547. PubMed ID: 31920342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA
    Kim HR; Cha YJ; Hong MH; Gandhi M; Levinson S; Jung I; Lee JG; Lee CY; Cho BC; Ha SJ; Shim HS
    Oncotarget; 2017 Oct; 8(50):87234-87243. PubMed ID: 29152077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability.
    Munari E; Zamboni G; Marconi M; Sommaggio M; Brunelli M; Martignoni G; Netto GJ; Moretta F; Mingari MC; Salgarello M; Terzi A; Picece V; Pomari C; Lunardi G; Cavazza A; Rossi G; Moretta L; Bogina G
    Oncotarget; 2017 Oct; 8(52):90123-90131. PubMed ID: 29163815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer.
    McLaughlin J; Han G; Schalper KA; Carvajal-Hausdorf D; Pelekanou V; Rehman J; Velcheti V; Herbst R; LoRusso P; Rimm DL
    JAMA Oncol; 2016 Jan; 2(1):46-54. PubMed ID: 26562159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project.
    Hirsch FR; McElhinny A; Stanforth D; Ranger-Moore J; Jansson M; Kulangara K; Richardson W; Towne P; Hanks D; Vennapusa B; Mistry A; Kalamegham R; Averbuch S; Novotny J; Rubin E; Emancipator K; McCaffery I; Williams JA; Walker J; Longshore J; Tsao MS; Kerr KM
    J Thorac Oncol; 2017 Feb; 12(2):208-222. PubMed ID: 27913228
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reliability of Small Biopsy Samples Compared With Resected Specimens for the Determination of Programmed Death-Ligand 1 Expression in Non--Small-Cell Lung Cancer.
    Kitazono S; Fujiwara Y; Tsuta K; Utsumi H; Kanda S; Horinouchi H; Nokihara H; Yamamoto N; Sasada S; Watanabe S; Asamura H; Tamura T; Ohe Y
    Clin Lung Cancer; 2015 Sep; 16(5):385-90. PubMed ID: 25937270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Erber R; Stöhr R; Herlein S; Giedl C; Rieker RJ; Fuchs F; Ficker JH; Hartmann A; Veltrup E; Wirtz RM; Brueckl WM
    Anticancer Res; 2017 Dec; 37(12):6771-6778. PubMed ID: 29187455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 immunohistochemical assays for assessment of therapeutic strategies involving immune checkpoint inhibitors in non-small cell lung cancer: a comparative study.
    Kim H; Kwon HJ; Park SY; Park E; Chung JH
    Oncotarget; 2017 Nov; 8(58):98524-98532. PubMed ID: 29228707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
    Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
    Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Programmed death ligand 1 expression and CD8
    Zhou J; Gong Z; Jia Q; Wu Y; Yang ZZ; Zhu B
    Biochem Biophys Res Commun; 2018 Apr; 498(4):751-757. PubMed ID: 29526752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discrepancy in Programmed Cell Death-Ligand 1 Between Primary and Metastatic Non-small Cell Lung Cancer.
    Takamori S; Toyokawa G; Okamoto I; Takada K; Kozuma Y; Matsubara T; Haratake N; Akamine T; Katsura M; Mukae N; Shoji F; Okamoto T; Oda Y; Iwaki T; Iihara K; Nakanishi Y; Maehara Y
    Anticancer Res; 2017 Aug; 37(8):4223-4228. PubMed ID: 28739710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples.
    Casadevall D; Clavé S; Taus Á; Hardy-Werbin M; Rocha P; Lorenzo M; Menéndez S; Salido M; Albanell J; Pijuan L; Arriola E
    Clin Lung Cancer; 2017 Nov; 18(6):682-691.e5. PubMed ID: 28549836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer.
    Scheel AH; Baenfer G; Baretton G; Dietel M; Diezko R; Henkel T; Heukamp LC; Jasani B; Jöhrens K; Kirchner T; Lasitschka F; Petersen I; Reu S; Schildhaus HU; Schirmacher P; Schwamborn K; Sommer U; Stoss O; Tiemann M; Warth A; Weichert W; Wolf J; Büttner R; Rüschoff J
    Histopathology; 2018 Feb; 72(3):449-459. PubMed ID: 28851100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation of PD-L1 Biomarker Testing Methods for PD-1 Axis Inhibition in Non-squamous Non-small Cell Lung Cancer.
    Sheffield BS; Fulton R; Kalloger SE; Milne K; Geller G; Jones M; Jacquemont C; Zachara S; Zhao E; Pleasance E; Laskin J; Jones SJ; Marra MA; Yip S; Nelson BH; Gown AM; Ho C; Ionescu DN
    J Histochem Cytochem; 2016 Oct; 64(10):587-600. PubMed ID: 27591097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of PD-L1 Expression in Patients with Surgically Resected Non-Small-Cell Lung Cancer.
    Igawa S; Sato Y; Ryuge S; Ichinoe M; Katono K; Hiyoshi Y; Otani S; Nagashio R; Nakashima H; Katagiri M; Sasaki J; Murakumo Y; Satoh Y; Masuda N
    Oncology; 2017; 92(5):283-290. PubMed ID: 28222447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors Influencing Concordance of PD-L1 Expression between Biopsies and Cytological Specimens in Non-Small Cell Lung Cancer.
    Mansour MSI; Hejny K; Johansson F; Mufti J; Vidis A; Mager U; Dejmek A; Seidal T; Brunnström H
    Diagnostics (Basel); 2021 Oct; 11(10):. PubMed ID: 34679625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Heymann JJ; Bulman WA; Swinarski D; Pagan CA; Crapanzano JP; Haghighi M; Fazlollahi L; Stoopler MB; Sonett JR; Sacher AG; Shu CA; Rizvi NA; Saqi A
    Cancer Cytopathol; 2017 Dec; 125(12):896-907. PubMed ID: 29024471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer.
    Lin G; Fan X; Zhu W; Huang C; Zhuang W; Xu H; Lin X; Hu D; Huang Y; Jiang K; Miao Q; Li C
    Oncotarget; 2017 Oct; 8(48):83986-83994. PubMed ID: 29137398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.